In-vitro synergistic activity of the combination of ampicillin and arbekacin against vancomycin-and high-level gentamicin-resistant Enterococcus faecium with the aph(2”)-Id gene

Carlier, 1990, Emergence of 4′,4”-aminoglycoside nucleotidyltransferase in enterococci, Antimicrob Agents Chemother, 34, 1565, 10.1128/AAC.34.8.1565 Chow, 1998, In vitro susceptibility and molecular analysis of gentamicin-resistant enterococci, Diagn Microbiol Infect Dis, 32, 141, 10.1016/S0732-8893(98)00056-X Ferretti, 1986, Nucleotide sequence analysis of the gene specifying the bifunctional 6′-amino glycoside acetyltransferase 2“-aminoglycoside phosphotransferase enzyme in Streptococcus faecalis and identification and cloning of gene regions specifying the two activities, J Bacteriol, 167, 631, 10.1128/jb.167.2.631-638.1986 Foulds, 1986, Pharmacokinetics of sulbactam/ampicillin in humans, Rev Infect Dis, 8, S503, 10.1093/clinids/8.Supplement_5.503 Hotta, 1996, Enzymatic 2′-N-acetylation of arbekacin and antibiotic activity of its product, J Antibiotics, 49, 458, 10.7164/antibiotics.49.458 Kariyama, 1998, In-vitro activity of the combination of ampicillin and arbekacin against high-level gentamicin-resistant enterococci, J Antimicrob Chemother, 42, 836, 10.1093/oxfordjournals.jac.a020872 Knapp, C., & Moody, J. A. (1992). Tests to assess bactericidal activity. Clinical Microbiology Procedures Handbook, vol. 1. In H. D. Isenberg (Ed.), Washington, DC: American Society for Microbiology: pp 5.16.21–5.16.29). Kondo, 1993, Structures of enzymatically modified products of arbekacin by methicillin-resistant Staphylococcus aureus, J Antibiotics, 46, 310, 10.7164/antibiotics.46.310 National Committee for Clinical Laboratory Standards (NCCLS). (1999). Approved Standard M7–A5: Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically, (5th ed.) Villanova, PA:NCCLS. Osakabe, 1996, The utility and dosage and administration of arbekacin in patients with MRSA infection, Antibiotics Chemother, 12, 120 Physicians’ Desk Reference. (1998). (52nd ed.) Montvale NJ: Medical Economics Company, p 2210. Thal, 1993, Molecular characterization of highly gentamicin-resistant Enterococcus faecalis isolates lacking high-level streptomycin resistance, Antimicrob Agents Chemother, 37, 134, 10.1128/AAC.37.1.134 Trieu-Cuot, 1983, Nucleotide sequence of the Streptococcus faecalis plasmid gene encoding the 3′5”-aminoglycoside phosphotransferase type III, Gene, 23, 331, 10.1016/0378-1119(83)90022-7 Tsai, S. F., Zervos, M. J., Clewell, D. B., Donabedian, S. M., Sahm, D. F., Chow, J. W. (1998). A new high-level gentamicin resistance gene. aph(2”)-Id, in Enterococcus sp Antimicrob Agents Chemother, 42, 1229–1232. Yamamoto, 1986, Phase-one clinical study on habekacin, Chemotherapy, 34, S104 You, 2000, In-vitro activity of arbekacin alone and in combination with vancomycin against gentamicin- and methicillin-resistant Staphylococcus aureus, Diagn Microbiol Infect Dis, 36, 37, 10.1016/S0732-8893(99)00104-2